Clinical Psychopharmacology and Neuroscience Papers in Press available online.

Hydroxychloroquine, Anti-IL-6 and corticoid treatments of acute Covid-19 infection: psychiatric symptoms and mental disorders 4 months later.
Matthieu Gasnier 1,2,*, Walid Choucha 1,2, David Montani 3, Nicolas Noël 4, Céline Versuyft 2,5, Francois Radiguer 6, Xavier Monnet 7, Laurent Becquemont 2,8, Emmanuelle Corruble 1,2, Romain Colle 1,2
1Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Mood Center Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France, 2MOODS Team, INSERM 1018, CESP (Centre de Recherche en Epidémiologie et Santé des Populations), Université Paris-Saclay, Faculté de Médecine Paris-Saclay, Le Kremlin Bicêtre, F-94275, France, 3Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, Inserm UMR_S999, Le Kremlin-Bicêtre, F-94275 France, 4Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, Hôpital de Bicêtre, F-94275, France, 5Service de génétique moléculaire et pharmacogénétique, hôpital Bicêtre, AP-HP, 94270 Kremlin-Bicêtre, France; Université Paris-Sud, Kremlin-Bicêtre, 94270 Kremlin-Bicêtre, France; Division d'immunovirologie, IDMIT, 92260 Fontenay-aux-Roses, France, 6Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, Le Kremlin-Bicêtre, F-94275, France, 7Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, Inserm UMR_S999, FHU SEPSIS, Le Kremlin-Bicêtre, F-94275, France , 8Centre de Recherche Clinique, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France
Psychiatric symptoms and mental disorders are common after Coronavirus Disease-19 (COVID-19). Some drugs used to treat acute COVID-19 have psychiatric side effects. We assessed the psychiatric symptoms and mental disorders of patients treated for acute COVID-19 with hydroxychloroquine (HCQ), interleukin-6 receptor antagonists (anti-IL-6), and corticoids (CTC) 4 months after infection. 177 patients were evaluated. In a multivariate analysis, HCQ was associated with significant anxiety symptoms (OR=5.9, CI95 [1.8 ; 20.0], p=0.003) and mental disorders (OR=4.1, CI95 [1.2 ; 13.9], p=0.02). In a bivariate analysis with propensity matched cohorts, HCQ was associated with significant anxiety symptoms (9 patients (50.0%) with significant symptoms in the HCQ group versus 15 (20.1 %) in the control group, OR = 3.8, CI95 [1.3;11.3], p = 0.01). Anti-IL-6 and CTC were not associated with significant psychiatric symptoms or mental disorders. We recommend monitoring psychiatric symptoms, especially anxiety, in patients treated with HCQ during COVID-19 infection. Further studies with larger samples and prospective assessments are needed to confirm our results.
Accepted Manuscript [Submitted on 2022-02-25, Accepted on 2022-06-08]